Dual-Action Cancer Therapy with Targeted Porous Silicon Nanovectors.
Anna Cifuentes-RiusAngela IvaskEster SporlederIshdeep KaurYasmin AssanShasha RaoDavid WartherClive A PrestidgeJean-Olivier DurandNicolas H VoelckerPublished in: Small (Weinheim an der Bergstrasse, Germany) (2017)
There is a pressing need to develop more effective therapeutics to fight cancer. An idyllic chemotherapeutic is expected to overcome drug resistance of tumors and minimize harmful side effects to healthy tissues. Antibody-functionalized porous silicon nanoparticles loaded with a combination of chemotherapy drug and gold nanoclusters (AuNCs) are developed. These nanocarriers are observed to selectively deliver both payloads, the chemotherapy drug and AuNCs, to human B cells. The accumulation of AuNCs to target cells and subsequent exposure to an external electromagnetic field in the microwave region render them more susceptible to the codelivered drug. This approach represents a targeted two-stage delivery nanocarrier that benefits from a dual therapeutic action that results in enhanced cytotoxicity.
Keyphrases
- cancer therapy
- drug delivery
- locally advanced
- endothelial cells
- papillary thyroid
- drug release
- drug induced
- gene expression
- radiation therapy
- emergency department
- cell cycle arrest
- rectal cancer
- sensitive detection
- induced pluripotent stem cells
- metal organic framework
- oxidative stress
- fluorescent probe
- chemotherapy induced
- high resolution
- wound healing
- liquid chromatography
- tissue engineering